Targeting O-Acetyl-GD2 Ganglioside for Cancer ImmunotherapyReportar como inadecuado




Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Immunology Research - Volume 2017 2017, Article ID 5604891, 16 pages - https:-doi.org-10.1155-2017-5604891

Review Article

Inserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France

CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France

Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France

CHU Nantes, Hotel Dieu, Nantes, France

Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, USA

Correspondence should be addressed to Stéphane Birklé

Received 15 August 2016; Revised 18 November 2016; Accepted 8 December 2016; Published 5 January 2017

Academic Editor: Julie Boucau

Copyright © 2017 Julien Fleurence et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.





Autor: Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, François Paris, Andras Heczey, a

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados